1. Home
  2. GCTK vs ALZN Comparison

GCTK vs ALZN Comparison

Compare GCTK & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • ALZN
  • Stock Information
  • Founded
  • GCTK 2001
  • ALZN 2016
  • Country
  • GCTK United States
  • ALZN United States
  • Employees
  • GCTK N/A
  • ALZN N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • ALZN Medicinal Chemicals and Botanical Products
  • Sector
  • GCTK Health Care
  • ALZN Health Care
  • Exchange
  • GCTK Nasdaq
  • ALZN Nasdaq
  • Market Cap
  • GCTK 7.1M
  • ALZN 6.9M
  • IPO Year
  • GCTK N/A
  • ALZN 2021
  • Fundamental
  • Price
  • GCTK $2.17
  • ALZN $1.64
  • Analyst Decision
  • GCTK
  • ALZN
  • Analyst Count
  • GCTK 0
  • ALZN 0
  • Target Price
  • GCTK N/A
  • ALZN N/A
  • AVG Volume (30 Days)
  • GCTK 10.0K
  • ALZN 361.1K
  • Earning Date
  • GCTK 11-02-2024
  • ALZN 12-13-2024
  • Dividend Yield
  • GCTK N/A
  • ALZN N/A
  • EPS Growth
  • GCTK N/A
  • ALZN N/A
  • EPS
  • GCTK N/A
  • ALZN N/A
  • Revenue
  • GCTK N/A
  • ALZN N/A
  • Revenue This Year
  • GCTK N/A
  • ALZN N/A
  • Revenue Next Year
  • GCTK N/A
  • ALZN N/A
  • P/E Ratio
  • GCTK N/A
  • ALZN N/A
  • Revenue Growth
  • GCTK N/A
  • ALZN N/A
  • 52 Week Low
  • GCTK $0.67
  • ALZN $1.40
  • 52 Week High
  • GCTK $4.95
  • ALZN $33.00
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 41.99
  • ALZN 40.84
  • Support Level
  • GCTK $2.11
  • ALZN $1.58
  • Resistance Level
  • GCTK $2.29
  • ALZN $1.90
  • Average True Range (ATR)
  • GCTK 0.10
  • ALZN 0.14
  • MACD
  • GCTK -0.02
  • ALZN 0.05
  • Stochastic Oscillator
  • GCTK 50.49
  • ALZN 39.53

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: